TTR and nonischemic cardiomyopathy: Another siRNA treatment, patisiran, which is delivered via liposome, was recently FDA approved for the treatment of transthyretin-related hereditary amyloidosis, a rare autosomal dominant disease which results in misfolded transthyretin and leads to diffuse polyneuropathy and nonischemic cardiomyopathy [139].